First Horizon Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

First Horizon Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$7.23K	Hold	516	–	–	﹤0.01%	1766
2025 Q1	$8.07K	Hold	516	–	–	﹤0.01%	1677
2024 Q4	$7.19K	Hold	516	–	–	﹤0.01%	1714
2024 Q3	$4.8K	Hold	516	–	–	﹤0.01%	1806
2024 Q2	$4.8K	Sell	516 -46	-8%	-$416	﹤0.01%	1770
2024 Q1	$5.57K	Hold	562	–	–	﹤0.01%	1786
2023 Q4	$1.81K	Hold	562	–	–	﹤0.01%	2053
2023 Q3	$2.98K	Hold	562	–	–	﹤0.01%	1885
2023 Q2	$5.36K	Hold	562	–	–	﹤0.01%	1771
2023 Q1	$6.18K	Buy	562 +259	+85%	+$3.75K	﹤0.01%	1747
2022 Q4	$4.48K	Hold	303	–	–	﹤0.01%	1820
2022 Q3	$5K	Buy	303 +128	+73%	+$2.9K	﹤0.01%	1747
2022 Q2	$3K	Buy	+175	New	+$3.59K	﹤0.01%	1953

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

First Horizon Advisors's ARQT Position: Q2 2025 in Review

First Horizon Advisors held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2025 at 516 shares worth $7.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

First Horizon Advisors first reported a position in ARQT in Q2 2022 and has held it in 13 quarters since. The position peaked at $8.07K in Q1 2025. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

First Horizon Advisors held 516 shares of Arcutis Biotherapeutics worth $7.23K as of Q2 2025.
First Horizon Advisors left its Arcutis Biotherapeutics share count unchanged in Q2 2025.
Arcutis Biotherapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1766 holding.
First Horizon Advisors first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 13 quarters since.
First Horizon Advisors's Arcutis Biotherapeutics position peaked at $8.07K in Q1 2025.
230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.